US equities |
MU $878.84 ▼-5.63% NVDA $214.13 ▼-1.43% TSLA $354.72 ▼-2.13% AAPL $343.46 ▲+0.43% META $709.33 ▼-3.72% MSFT $529.05 ▼-1.93% SPCX $146.03 ▼-1.74% AMD $528.75 ▼-5.95%
FinancialContent

Mereo BioPharma Group plc - American Depositary Shares (NQ:MREO)

0.3030 -0.0061 (-1.97%)
Delayed Quote Updated: 4:00 PM EDT, Oct 16, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Mereo BioPharma Group plc - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 Next >
News headline image
Why Is Mereo BioPharma Stock Trading Higher Today? ↗
Ultragenyx Pharmaceutical Inc (NASDAQ: RARE) and Mereo BioPharma Group plc (NASDAQ: MREO) released interim data from the Phase 2 portion of the Phase 2/3 Orbit  
Via Benzinga
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Streamline Health Solutions Shares Are Trading Lower By Over 68%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗
Gainers MingZhu Logistics Holdings Limited (NASDAQ: YGMZ) shares gained 64% to $0.7798 after gaining more than 10% on Friday. 
Via Benzinga
News headline image
Why Ultragenyx Pharma Stock Is Trading Higher Premarket Today ↗
 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday ↗
It's time to start off the week with a breakdown of the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
News headline image
Ultragenyx and Mereo BioPharma Announce Interim Phase 2 Data from Phase 2/3 Orbit Study Demonstrating Setrusumab (UX143) Significantly Reduced Fracture Rates in Patients with Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.; Mereo Biopharma
Via GlobeNewswire
News headline image
Ultragenyx to Present Setrusumab (UX143) Update at ASBMR 2023 Including New Data from Phase 2/3 Orbit Study in Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
Mereo BioPharma to Participate in Fireside Chat at the 2023 Cantor Global Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Reports Interim Financial Results for the Six Months Ended June 30, 2023 and Provides Corporate Update
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Ultragenyx Announces First Patients Dosed in Phase 3 Program Evaluating Setrusumab (UX143) for the Treatment of Osteogenesis Imperfecta (OI)
From Ultragenyx Pharmaceutical Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Wednesday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Bluejay Diagnostics Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Visionary Education Technology Holdings Group Inc. (NASDAQ: VEDU) shares rose 85.8% to $0.7985 in pre-market trading. 
Via Benzinga
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday ↗
It's time for another dive into the latest pre-market stock movers as we check out all of the news moving shares on Tuesday morning! 
Via InvestorPlace
News headline image
Mereo BioPharma to Present at the Jefferies Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Phase 2 Data from “ASTRAEUS” Trial of Mereo BioPharma’s Alvelestat in Alpha-1 Antitrypsin Deficiency-associated Lung Disease Presented at the 2023 American Thoracic Society International Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma to Participate in Fireside Chat at the 22nd Annual Needham Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Reports Full Year 2022 Financial Results and Recent Highlights
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Provides Regulatory Updates on Alvelestat for the Treatment of Alpha-1-Antitrypsin Deficiency-Associated Lung Disease
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Why Blue Apron Shares Are Trading Lower By 12%; Here Are 20 Stocks Moving Premarket ↗
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares rose 52.5% to $0.7050 in pre-market trading after jumping over 72% on Friday. 
Via Benzinga
News headline image
Mereo BioPharma to Participate in Fireside Chat at the SVB Securities Global Biopharma Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Monday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Silo Pharma Shares Are Trading Higher By Around 64%? Here Are 46 Stocks Moving In Friday's Mid-Day Session ↗
Gainers Dermata Therapeutics, Inc. (NASDAQ: DRMA) shares jumped 121% to $0.4428 after the company requested to withdraw its registration on Form S-1 and said it does not intend to pursue the... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session ↗
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Why Venus Concept Shares Are Trading Higher By Over 63%? Here Are 58 Stocks Moving In Wednesday's Mid-Day Session ↗
Gainers Sintx Technologies, Inc. (NASDAQ: SINT) shares climbed 81.4% to $13.55 after the company was awarded Phase I contract for $150,000 from the Missile Defense Agency for electrochemical... 
Via Benzinga
News headline image
Mereo BioPharma to Participate in Fireside Chat at the Jefferies London Healthcare Conference
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Received Notification of Nasdaq Minimum Bid Price Deficiency
From Mereo BioPharma Group plc
Via GlobeNewswire
News headline image
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
From Mereo BioPharma Group plc
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 Next >